203 related articles for article (PubMed ID: 19914963)
1. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
[TBL] [Abstract][Full Text] [Related]
2. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
3. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Belhocine T; Hustinx R; Rigo P; Fillet G
Ann Oncol; 2003 Jan; 14(1):123-30. PubMed ID: 12488304
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
5. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma.
Xie P; Yue JB; Fu Z; Feng R; Yu JM
Ann Oncol; 2010 May; 21(5):1078-82. PubMed ID: 19914960
[TBL] [Abstract][Full Text] [Related]
8. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
9. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
10. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures.
Picardi M; Pugliese N; Cirillo M; Zeppa P; Cozzolino I; Ciancia G; Pettinato G; Salvatore C; Quintarelli C; Pane F
Radiology; 2014 Jul; 272(1):262-74. PubMed ID: 24708193
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy.
Petrausch U; Samaras P; Haile SR; Veit-Haibach P; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schäefer NG
Ann Oncol; 2010 Aug; 21(8):1694-1698. PubMed ID: 20139151
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
14. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen.
Picardi M; Soricelli A; Grimaldi F; Nicolai E; Gallamini A; Pane F
Ann Oncol; 2011 Mar; 22(3):671-680. PubMed ID: 20693297
[TBL] [Abstract][Full Text] [Related]
15. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
16. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
[TBL] [Abstract][Full Text] [Related]
17. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
18. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
Spaepen K; Stroobants S; Dupont P; Thomas J; Vandenberghe P; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Br J Haematol; 2001 Nov; 115(2):272-8. PubMed ID: 11703321
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
